Literature DB >> 12883880

Expression of functional protease-activated receptor 1 in human prostate cancer cell lines.

Jian Liu1, Manuela Bastian, Peter Kohlschein, Peter Schuff-Werner, Michael Steiner.   

Abstract

Functional protease-activated receptors (PAR) are expressed by a variety of malignant cells. In the present study, RT-PCR assays demonstrated the expression of the thrombin receptor PAR-1 mRNA in human prostate cancer cell lines DU 145, LnCAP, and SV40-immortalized human prostate epithelial cell line PNT1A. In contrast, the additional thrombin receptors PAR-3 and PAR-4 were not detected. PAR-1 protein localized to the cellular surface was detected by flow cytometry in all three cell lines. To demonstrate the functional importance of the PAR-1, the effects of different concentrations of thrombin on cell proliferation kinetics were assessed. The treatment of growth-arrested cells with varying concentrations of thrombin demonstrated dose- and time-dependent effects. At low concentration (<0.5 U/ml), thrombin induced proliferation of all prostate-derived cell lines. Thrombin at higher concentration (1.0 U/ml) initially stimulated PNT1A and LnCAP cells to proliferate (time of thrombin application 24 h and 48 h) followed by inhibited growth when assessed after 72 h of incubation. In contrast, 1.0 U/ml thrombin caused earlier inhibition of DU 145 proliferation starting at 48 h of incubation. Our results suggest that PAR-1 mediates the proliferation-modulating effects of thrombin on prostate cancer cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12883880     DOI: 10.1007/s00240-003-0309-2

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  36 in total

1.  Expression of prothrombin fragment 1+2 in cancer tissue as an indicator of local activation of blood coagulation.

Authors:  M Z Wojtukiewicz; M Rucinska; L Zimnoch; J Jaromin; Z Piotrowski; M Rózanska-Kudelska; W Kisiel; B J Kudryk
Journal:  Thromb Res       Date:  2000-03-01       Impact factor: 3.944

2.  Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo.

Authors:  M L Nierodzik; F Kajumo; S Karpatkin
Journal:  Cancer Res       Date:  1992-06-15       Impact factor: 12.701

3.  EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF.

Authors:  N Prenzel; E Zwick; H Daub; M Leserer; R Abraham; C Wallasch; A Ullrich
Journal:  Nature       Date:  1999 Dec 23-30       Impact factor: 49.962

4.  Concentration-dependent dual effect of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells.

Authors:  J Zain; Y Q Huang; X Feng; M L Nierodzik; J J Li; S Karpatkin
Journal:  Blood       Date:  2000-05-15       Impact factor: 22.113

5.  Signaling from protease-activated receptor-1 inhibits migration and invasion of breast cancer cells.

Authors:  L Kamath; A Meydani; F Foss; A Kuliopulos
Journal:  Cancer Res       Date:  2001-08-01       Impact factor: 12.701

6.  D-Phe-Pro-ArgCH2C1-A selective affinity label for thrombin.

Authors:  C Kettner; E Shaw
Journal:  Thromb Res       Date:  1979       Impact factor: 3.944

7.  Calcium signals in prostate cancer cells: specific activation by bone-matrix proteins.

Authors:  V Lecrone; W Li; R E Devoll; C Logothetis; M C Farach-Carson
Journal:  Cell Calcium       Date:  2000-01       Impact factor: 6.817

8.  Thrombomodulin expression in transitional cell carcinoma.

Authors:  N G Ordóñez
Journal:  Am J Clin Pathol       Date:  1998-09       Impact factor: 2.493

9.  Thrombin stimulates melanoma tumor-cell binding to endothelial cells and subendothelial matrix.

Authors:  A Klepfish; M A Greco; S Karpatkin
Journal:  Int J Cancer       Date:  1993-04-01       Impact factor: 7.396

10.  Presence of the seven transmembrane thrombin receptor on human tumour cells: effect of activation on tumour adhesion to platelets and tumor tyrosine phosphorylation.

Authors:  M L Nierodzik; R M Bain; L X Liu; M Shivji; K Takeshita; S Karpatkin
Journal:  Br J Haematol       Date:  1996-02       Impact factor: 6.998

View more
  9 in total

Review 1.  Proteinase-activated receptors in the lower urinary tract.

Authors:  James D Moffatt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-02-10       Impact factor: 3.000

Review 2.  Expression of proteinase-activated receptor 1-4 (PAR 1-4) in human cancer.

Authors:  Andrea Pia Elste; Iver Petersen
Journal:  J Mol Histol       Date:  2010-06-20       Impact factor: 2.611

3.  Oral thrombostatin FM19 inhibits prostate cancer.

Authors:  Marvin T Nieman; Gretchen LaRusch; Chao Fang; Yihua Zhou; Alvin H Schmaier
Journal:  Thromb Haemost       Date:  2010-09-30       Impact factor: 5.249

4.  Protease-activated receptor-1 (PAR-1) promotes the motility of human melanomas and is associated to their metastatic phenotype.

Authors:  Antonietta Silini; Carmen Ghilardi; Camilla Ardinghi; Sergio Bernasconi; Paolo Oliva; Fabio Carraro; Antonella Naldini; Maria Rosa Bani; Raffaella Giavazzi
Journal:  Clin Exp Metastasis       Date:  2009-12-20       Impact factor: 5.150

5.  The impaired viability of prostate cancer cell lines by the recombinant plant kallikrein inhibitor.

Authors:  Joana Gasperazzo Ferreira; Paula Malloy Motta Diniz; Cláudia Alessandra Andrade de Paula; Yara Aparecida Lobo; Edgar Julian Paredes-Gamero; Thaysa Paschoalin; Amanda Nogueira-Pedro; Paloma Korehisa Maza; Marcos Sergio Toledo; Erika Suzuki; Maria Luiza Vilela Oliva
Journal:  J Biol Chem       Date:  2013-03-19       Impact factor: 5.157

6.  Towards precise classification of cancers based on robust gene functional expression profiles.

Authors:  Zheng Guo; Tianwen Zhang; Xia Li; Qi Wang; Jianzhen Xu; Hui Yu; Jing Zhu; Haiyun Wang; Chenguang Wang; Eric J Topol; Qing Wang; Shaoqi Rao
Journal:  BMC Bioinformatics       Date:  2005-03-17       Impact factor: 3.169

7.  Proteinase-activated receptor-1 and immunomodulatory effects of a PAR1-activating peptide in a mouse model of prostatitis.

Authors:  M Mark Stanton; Lisa K Nelson; Hallgrimur Benediktsson; Morley D Hollenberg; Andre G Buret; Howard Ceri
Journal:  Mediators Inflamm       Date:  2013-12-29       Impact factor: 4.711

Review 8.  Inflammation and NF-κB Signaling in Prostate Cancer: Mechanisms and Clinical Implications.

Authors:  Jens Staal; Rudi Beyaert
Journal:  Cells       Date:  2018-08-29       Impact factor: 6.600

Review 9.  Thromboinflammatory Processes at the Nexus of Metabolic Dysfunction and Prostate Cancer: The Emerging Role of Periprostatic Adipose Tissue.

Authors:  Ibrahim AlZaim; Aya Al-Saidi; Safaa H Hammoud; Nadine Darwiche; Yusra Al-Dhaheri; Ali H Eid; Ahmed F El-Yazbi
Journal:  Cancers (Basel)       Date:  2022-03-25       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.